Cargando…
Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis
BACKGROUND: This study aimed to investigate the seroreactivity of Coronavirus disease 2019 (COVID-19) vaccination and its adverse events among systemic lupus erythematosus (SLE) patients, rheumatoid arthritis (RA) patients, and healthy controls (HCs). METHODS: A total of 60 SLE patients, 70 RA patie...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Masson SAS.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040458/ https://www.ncbi.nlm.nih.gov/pubmed/35486976 http://dx.doi.org/10.1016/j.biopha.2022.112997 |
_version_ | 1784694340744904704 |
---|---|
author | Wang, Peng Ni, Jing Chu, Ya-Ya Chen, Qing-Qing Wu, Guo-Cui Fang, Yang Chen, Cong Zhang, Ruo-Di Jiang, Ling-Qiong Zhao, Yan Fang, Xi He, Jun Wang, De-Guang Wang, Gui-Hong Pan, Hai-Feng |
author_facet | Wang, Peng Ni, Jing Chu, Ya-Ya Chen, Qing-Qing Wu, Guo-Cui Fang, Yang Chen, Cong Zhang, Ruo-Di Jiang, Ling-Qiong Zhao, Yan Fang, Xi He, Jun Wang, De-Guang Wang, Gui-Hong Pan, Hai-Feng |
author_sort | Wang, Peng |
collection | PubMed |
description | BACKGROUND: This study aimed to investigate the seroreactivity of Coronavirus disease 2019 (COVID-19) vaccination and its adverse events among systemic lupus erythematosus (SLE) patients, rheumatoid arthritis (RA) patients, and healthy controls (HCs). METHODS: A total of 60 SLE patients, 70 RA patients and 35 HCs, who received a complete inactivated COVID-19 vaccine (Vero cells) regimen, were recruited in the current study. Serum IgG and IgM antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) were determined by using chemiluminescent microparticle immunoassay (CMIA). RESULTS: There were no significant differences regarding the seroprevalences of IgG and IgM antibodies against SARS-CoV-2, and the self-reported vaccination-related adverse events among SLE patients, RA patients and HCs. The inactivated COVID-19 vaccines appeared to be well-tolerated and moderately immunogenic. In addition, case-only analysis indicated that in SLE patients, the disease manifestation of rash and anti-SSA autoantibody were associated with seroprevalence of IgG antibody against SARS-CoV-2, whereas the uses of ciclosporin and leflunomide had influence on the seroprevalence of IgM antibody against SARS-CoV-2. In RA patients, rheumatoid factor (RF) appeared to be associated with the seroprevalence of IgG antibody against SARS-CoV-2. CONCLUSION: Our study reveals that the seroprevalences of IgG and IgM antibodies against SARS-CoV-2 and vaccination-related adverse effects are similar among SLE, RA and HCs, suggesting that COVID-19 vaccine is safe and effective for SLE and RA patients to prevent from the pandemic of COVID-19. |
format | Online Article Text |
id | pubmed-9040458 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Author(s). Published by Elsevier Masson SAS. |
record_format | MEDLINE/PubMed |
spelling | pubmed-90404582022-04-26 Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis Wang, Peng Ni, Jing Chu, Ya-Ya Chen, Qing-Qing Wu, Guo-Cui Fang, Yang Chen, Cong Zhang, Ruo-Di Jiang, Ling-Qiong Zhao, Yan Fang, Xi He, Jun Wang, De-Guang Wang, Gui-Hong Pan, Hai-Feng Biomed Pharmacother Article BACKGROUND: This study aimed to investigate the seroreactivity of Coronavirus disease 2019 (COVID-19) vaccination and its adverse events among systemic lupus erythematosus (SLE) patients, rheumatoid arthritis (RA) patients, and healthy controls (HCs). METHODS: A total of 60 SLE patients, 70 RA patients and 35 HCs, who received a complete inactivated COVID-19 vaccine (Vero cells) regimen, were recruited in the current study. Serum IgG and IgM antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) were determined by using chemiluminescent microparticle immunoassay (CMIA). RESULTS: There were no significant differences regarding the seroprevalences of IgG and IgM antibodies against SARS-CoV-2, and the self-reported vaccination-related adverse events among SLE patients, RA patients and HCs. The inactivated COVID-19 vaccines appeared to be well-tolerated and moderately immunogenic. In addition, case-only analysis indicated that in SLE patients, the disease manifestation of rash and anti-SSA autoantibody were associated with seroprevalence of IgG antibody against SARS-CoV-2, whereas the uses of ciclosporin and leflunomide had influence on the seroprevalence of IgM antibody against SARS-CoV-2. In RA patients, rheumatoid factor (RF) appeared to be associated with the seroprevalence of IgG antibody against SARS-CoV-2. CONCLUSION: Our study reveals that the seroprevalences of IgG and IgM antibodies against SARS-CoV-2 and vaccination-related adverse effects are similar among SLE, RA and HCs, suggesting that COVID-19 vaccine is safe and effective for SLE and RA patients to prevent from the pandemic of COVID-19. The Author(s). Published by Elsevier Masson SAS. 2022-06 2022-04-26 /pmc/articles/PMC9040458/ /pubmed/35486976 http://dx.doi.org/10.1016/j.biopha.2022.112997 Text en © 2022 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Wang, Peng Ni, Jing Chu, Ya-Ya Chen, Qing-Qing Wu, Guo-Cui Fang, Yang Chen, Cong Zhang, Ruo-Di Jiang, Ling-Qiong Zhao, Yan Fang, Xi He, Jun Wang, De-Guang Wang, Gui-Hong Pan, Hai-Feng Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis |
title | Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis |
title_full | Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis |
title_fullStr | Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis |
title_full_unstemmed | Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis |
title_short | Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis |
title_sort | seroprevalence of sars-cov-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040458/ https://www.ncbi.nlm.nih.gov/pubmed/35486976 http://dx.doi.org/10.1016/j.biopha.2022.112997 |
work_keys_str_mv | AT wangpeng seroprevalenceofsarscov2specificantibodiesandvaccinationrelatedadverseeventsinsystemiclupuserythematosusandrheumatoidarthritis AT nijing seroprevalenceofsarscov2specificantibodiesandvaccinationrelatedadverseeventsinsystemiclupuserythematosusandrheumatoidarthritis AT chuyaya seroprevalenceofsarscov2specificantibodiesandvaccinationrelatedadverseeventsinsystemiclupuserythematosusandrheumatoidarthritis AT chenqingqing seroprevalenceofsarscov2specificantibodiesandvaccinationrelatedadverseeventsinsystemiclupuserythematosusandrheumatoidarthritis AT wuguocui seroprevalenceofsarscov2specificantibodiesandvaccinationrelatedadverseeventsinsystemiclupuserythematosusandrheumatoidarthritis AT fangyang seroprevalenceofsarscov2specificantibodiesandvaccinationrelatedadverseeventsinsystemiclupuserythematosusandrheumatoidarthritis AT chencong seroprevalenceofsarscov2specificantibodiesandvaccinationrelatedadverseeventsinsystemiclupuserythematosusandrheumatoidarthritis AT zhangruodi seroprevalenceofsarscov2specificantibodiesandvaccinationrelatedadverseeventsinsystemiclupuserythematosusandrheumatoidarthritis AT jianglingqiong seroprevalenceofsarscov2specificantibodiesandvaccinationrelatedadverseeventsinsystemiclupuserythematosusandrheumatoidarthritis AT zhaoyan seroprevalenceofsarscov2specificantibodiesandvaccinationrelatedadverseeventsinsystemiclupuserythematosusandrheumatoidarthritis AT fangxi seroprevalenceofsarscov2specificantibodiesandvaccinationrelatedadverseeventsinsystemiclupuserythematosusandrheumatoidarthritis AT hejun seroprevalenceofsarscov2specificantibodiesandvaccinationrelatedadverseeventsinsystemiclupuserythematosusandrheumatoidarthritis AT wangdeguang seroprevalenceofsarscov2specificantibodiesandvaccinationrelatedadverseeventsinsystemiclupuserythematosusandrheumatoidarthritis AT wangguihong seroprevalenceofsarscov2specificantibodiesandvaccinationrelatedadverseeventsinsystemiclupuserythematosusandrheumatoidarthritis AT panhaifeng seroprevalenceofsarscov2specificantibodiesandvaccinationrelatedadverseeventsinsystemiclupuserythematosusandrheumatoidarthritis |